Ajay Royan created and runs Mithril, a growth fund that makes concentrated investments in transformative and durable technology companies around the world.

Ajay and his team partner with innovators building companies in industries as diverse as cybersecurity, advanced medical devices, and fusion energy. Before forming Mithril, Ajay was a member of the core team that grew Clarium Capital into a multibillion-dollar macro fund.

He serves as an external advisor to Oak Ridge National Labs and the University of Michigan Risk Science Center. He was educated at Yale.

Kelly Barnes is a retired partner from PricewaterhouseCoopers (PwC). Ms. Barnes worked at PwC from 1988 to 2020, most recently serving as Global Health Industries Leader from 2018-2020 and as US Health Industries Leader from 2009-2020. Named one of Health Data Management’s Most Powerful Women in Healthcare IT, she moved seamlessly into actualizing innovative business and revenue models including digital solutions and collaborations that disrupted the healthcare industry. At PwC, she was relied upon for her ability to take the long view regarding brand health, reputation, and thought leadership during critical inflection points of change and growth. Ms. Barnes currently serves on the board of directors of Included Health and is a member of the Executive Advisory Board for the Walton College of Business at the University of Arkansas. She earned a B.S. in business administration and an MSA in Accounting from the University of Arkansas.

Senator William W. Bradley served in the U.S. Senate from 1979 to 1997 representing the state of New Jersey. In 2000, he was a candidate for the Democratic nomination for President of the United States.

Previously, he was chief outside advisor to McKinsey & Company’s nonprofit practice and was a Senior Advisor and Vice Chairman of the International Council of JP Morgan & Co. He has worked as an essayist for CBS Evening News and was a visiting professor at Stanford University, University of Notre Dame, and the University of Maryland. Senator Bradley has authored seven books on American politics, culture and economy, including his latest book We Can All Do Better.

Currently, he hosts American Voices, a weekly show on Sirius XM Satellite Radio that highlights the remarkable accomplishments of Americans both famous and unknown. Prior to serving in the Senate, he was an Olympic gold medalist in 1964 and a professional basketball player with the New York Knicks from 1967 to 1977 during which time they won two NBA championships. In 1982, he was elected to the Basketball Hall of Fame. Senator Bradley holds a B.A. degree in American History from Princeton University and an M.A. degree from Oxford University where he was a Rhodes Scholar.

Sam Conaway is a strategic senior leader in the medical device industry known for his compassion and entrepreneurial spirit. His experience in healthcare spans over 40 years, and he is driven to improve access to care for women and people of color.

As President, U.S. Cardiology Sales, Sam provides strategic direction for U.S. commercial cardiology sales which includes Atrial Fibrillation Solutions (LAAC & Electrophysiology Therapies), Cardiac Rhythm Management & Diagnostics and Interventional Cardiology & Structural Heart Therapies.  As a member of the Cardiology Group executive team and Chair of Close the Gap, a Boston Scientific health equity initiative, Sam influences commercial strategy and engagement across the entire Cardiology portfolio and leads cross-functional teams focused on strategic alliances that enable Boston Scientific’s compelling value proposition. The convergence of Sam’s leadership roles within Boston Scientific positions him to wrap meaning around innovation.

Sam was recognized by SAVOY Magazine (2022) as one of the Most Influential Black Executives in Corporate America, was recipient of Cardiovascular Research Foundation’s Inaugural Pulse-Setter Leader Award (2022) and honored by BlackDoctor.org in 2022 as one of fourteen Top Blacks in Healthcare.

Sam holds an MBA from the University of Maryland Global Campus, and a BS Degree from the University of Phoenix. Sam sits on the boards of JDP and the International Andreas Gruentzig Society.

Marc Elia is the founder of M28 Capital, a healthcare sector investment fund. Prior to that, from January 2012 to September 2019, Mr. Elia served as a partner at Bridger Capital, an investment fund. He is on the Board of Directors of Adagio Therapeutics, Adimab and SQZ Biotechnologies. Mr. Elia holds a B.A. in economics from Carleton College.

Clive Meanwell is Executive Chair and Founder of Population Health Partners, a global investment firm based in New York, San Francisco, and London, focused on technologies which arrest the drivers of common and burdensome health conditions such as stroke and heart disease, diabetes, lung diseases, chronic pain, anxiety, and depression. He is also Vice Chairman of BB Biotech, the Swiss investor in biotechnology. Clive leads Metsera, a private company developing medicines for metabolic diseases.

Clive was the founder, Chief Executive and Chief Innovation Officer of The Medicines Company, acquired by Novartis in early 2020 for $9.7 billion. Prior to that, he was a Partner at the venture capital firm MPM Capital, and before then, he held senior global executive positions with the Roche group working out of Switzerland and the United States. He trained in medicine, with post-graduate specialization in cancer treatment, cancer research, clinical trials, statistics, and epidemiology. He holds M.B., Ch.B., and M.D. cum laude degrees from the University of Birmingham, UK.

Dr. Harith Rajagopalan is Co-Founder and CEO of Fractyl Health, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners.

Prior to founding Fractyl Health, Harith was an academic cardiologist and physician-scientist. He received his B.S. in chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science.

After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women’s Hospital and completed a research fellowship at Harvard Medical School.

Amy Schulman is a healthcare investor and managing partner of the LS Polaris Innovation Fund. She is a highly respected leader in the biotech and pharmaceutical industries. Ms. Schulman joined Polaris Partners in 2014, simultaneously assuming the role of CEO of Arsia Therapeutics, a company acquired by Eagle Pharmaceuticals in 2016. In 2015, Ms. Schulman co-founded Lyndra, where she is CEO. She became CEO and Executive Chair of Olivo Laboratories in 2017, which sold its cosmetic business to Shiseido in 2018, and serves as Executive Chair of SQZ Biotech.

Prior to joining Polaris, Schulman was the general counsel of Pfizer, president of Pfizer Nutrition, and ran Pfizer consumer healthcare after the nutrition business was sold to Nestle in 2012. She is the recipient of numerous awards including: Scientific American’s “2015 Worldview 100 List”, Fierce Biotech’s 2014 “Top 15 Women in Biotech”, and Fortune Magazine’s 2013 “50 Most Powerful Women in Business”.

Amy is a Senior Lecturer at Harvard Business School where she teaches Leadership and Corporate Accountability. She serves on the Board of Directors of Alnylam Pharmaceuticals, Ironwood Pharmaceuticals, and the Whitehead Institute.

She is a Phi Beta Kappa graduate of Wesleyan University and earned her J.D. from Yale Law School.